Reaction

Fibula Fracture reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,863 reports · 76 co-occurring drugs

As of the last recalculation, Fibula Fracture appears in 2,863 FAERS reports alongside 76 co-occurring drug terms. The strongest observed disproportionality signal is EMTRICITABINE AND TENOFOVIR ALAFENAMIDE (PRR 28.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Emtricitabine And Tenofovir Alafenamide	43	28.0	28.1
Alendronate Sodium	338	27.5	27.6
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	31	25.3	25.4
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	33	24.1	24.2
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	51	20.8	20.9
Emtricitabine And Tenofovir Disoproxil Fumarate	111	18.4	18.4
Tenofovir Disoproxil Fumarate	49	10.9	11.0
Risedronate Sodium	40	9.5	9.5
Tizanidine Hydrochloride	22	8.9	8.9
Alendronate Sodium Tablet	21	8.3	8.3
Ascorbic Acid	26	8.2	8.2
Dolutegravir Sodium	10	8.1	8.1
Zoledronic Acid	44	8.1	8.1
Romosozumab-Aqqg	15	8.1	8.1
Magnesium Hydroxide	14	7.6	7.6
Cimetidine	10	7.6	7.6
Calcium Carbonate	67	7.4	7.4
Cyclobenzaprine Hydrochloride	9	7.3	7.3
Hyoscyamine Sulfate	9	7.1	7.2
Tizanidine	23	7.1	7.1
Sucralfate	23	7.0	7.0
Dicyclomine Hydrochloride	13	6.7	6.7
Amlodipine Besylate And Valsartan	10	6.6	6.6
Raloxifene Hydrochloride	13	6.5	6.5
Tolterodine Tartrate	8	6.5	6.5
Benzonatate	14	6.2	6.2
Carisoprodol	16	6.1	6.1
Teriparatide	89	5.9	5.9
Rizatriptan Benzoate	8	5.7	5.7
Ropinirole	12	5.7	5.7
Sucralfate Oral	11	5.6	5.6
Sucralfate Oral Suspension	11	5.6	5.6
Trazodone Hydrochloride	12	5.6	5.6
Cyclobenzaprine	37	5.4	5.5
Calcium, Magnesium, Potassium, And Sodium Oxybates	6	5.1	5.1
Upadacitinib	55	5.0	5.0
Pioglitazone	29	4.9	4.9
Interferon Beta-1A	124	4.8	4.8
Cetirizine Hcl	6	4.8	4.8
Modafinil	21	4.8	4.8
Dalfampridine	46	4.7	4.7
Fesoterodine Fumarate	7	4.7	4.7
Iron Sucrose	6	4.6	4.6
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl	31	4.5	4.5
Baclofen	53	4.5	4.5
Valsartan And Hydrochlorothiazide	8	4.3	4.3
Estrogens, Conjugated	32	4.0	4.0
Etonogestrel And Ethinyl Estradiol	12	3.9	3.9
Conjugated Estrogens	31	3.9	3.9
Interferon Beta-1B	10	3.8	3.8
Ocrelizumab	32	3.8	3.8
Oxybutynin	15	3.7	3.7
Paricalcitol	7	3.6	3.6
Acetaminophen And Codeine	6	3.6	3.6
Denosumab	96	3.5	3.5
Dofetilide	5	3.5	3.5
Armodafinil	10	3.5	3.5
Sodium Oxybate	31	3.4	3.4
Siponimod	4	3.3	3.3
Natalizumab	80	3.3	3.3
Vilazodone Hydrochloride	4	3.2	3.2
Risankizumab-Rzaa	35	3.1	3.1
Conjugated Estrogens And Medroxyprogesterone Acetate	10	3.1	3.1
Dimethyl Fumarate	49	2.9	2.9
Eltrombopag Olamine	8	2.5	2.5
Suvorexant	4	2.2	2.2
Abaloparatide	8	2.0	2.0
Sarilumab	7	1.9	1.9
Fremanezumab-Vfrm	3	1.9	1.9
Apalutamide	3	1.9	1.9
Tafamidis	3	1.9	1.9
Diroximel Fumarate	3	1.8	1.8
Abemaciclib	5	1.8	1.8
Emicizumab	3	1.8	1.8
Peginterferon Beta-1A	3	1.7	1.7
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	6	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.